The Man Who Made Millions by Marketing Monoclonal Antibodies

SAN DIEGO—When Ivor Royston founded his first biotech company in 1978, the 33-year-old assistant professor at the University of California, San Diego had no idea it would make him so rich and...infamous. Royston did know he was taking a risk. But his idea, to start the first company in the nation to sell monoclonal antibodies to other labs, was so compelling that he decided to gamble his career at UCSD. “I had only been there a year. I wasn’t even tenured,” recalls

Written byAnn Gibbons
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

SAN DIEGO—When Ivor Royston founded his first biotech company in 1978, the 33-year-old assistant professor at the University of California, San Diego had no idea it would make him so rich and...infamous.

Royston did know he was taking a risk. But his idea, to start the first company in the nation to sell monoclonal antibodies to other labs, was so compelling that he decided to gamble his career at UCSD. “I had only been there a year. I wasn’t even tenured,” recalls Royston, going on to say: "I thought it might jeopardize my career, but I also had a gut feeling that this was the right thing to do,”

Financially, the grand gamble paid off. Today, at 43, Royston is immensely wealthy, the founder of two biotechnology companies and still a university professor. He works in his lab, conducts clinical trials at the UCSD medical center, and spends a couple ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies